Role of afatinib in the treatment of advanced lung squamous cell carcinoma

Código QR

Role of afatinib in the treatment of advanced lung squamous cell carcinoma

Tiziana Vavalà ASL CN1, SC Oncologia, Ospedale Civile di Saluzzo, Saluzzo, Cuneo, Italy Abstract: Lung cancer treatment has considerably changed over the last few years: the identification of druggable oncogenic alterations and innovative immunotherapic approaches granted lung cancer pati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Vavalà T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	lung cancer NSCLC squamous cell lung carcinoma afatinib EGFR TKI Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/837228eaa698435f878962933e6ea4e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
por: You-Yi Chen, et al.
Publicado: (2021)

Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Ziyu Wang, et al.
Publicado: (2021)

IgA Vasculitis in a Lung Cancer Patient During Chemoradiotherapy
por: Taoka M, et al.
Publicado: (2021)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)

Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report
por: Lander Van Acker, et al.
Publicado: (2021)

Identification of lncRNA–miRNA–mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor
por: Ting Wang, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Hongfu Cai, et al.
Publicado: (2021)

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
por: Mountzios G, et al.
Publicado: (2021)

ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί
por: Jeon-Soo Lee, et al.
Publicado: (2021)

Gender specific eRNA TBX5-AS1 as the immunological biomarker for male patients with lung squamous cell carcinoma in pan-cancer screening
por: Tao Yan, et al.
Publicado: (2021)

Integrated analyses of copy number variations and gene differential expression in lung squamous-cell carcinoma
por: Yang,Zhao, et al.
Publicado: (2015)

Silmitasertib-induced macropinocytosis promoting DDP intracellular uptake to enhance cell apoptosis in oral squamous cell carcinoma
por: Shaojuan Song, et al.
Publicado: (2021)

Circulating Natural Autoantibodies to HER2-Derived Peptides Performed Antitumor Effects on Oral Squamous Cell Carcinoma
por: Xiu Liu, et al.
Publicado: (2021)

The role of ferroptosis in lung cancer
por: Sikai Wu, et al.
Publicado: (2021)

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
por: Shuluan Li, et al.
Publicado: (2021)

Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma
por: Xing-xing Huo, et al.
Publicado: (2021)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Taichi Miyawaki, et al.
Publicado: (2021)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Yurong Wang, et al.
Publicado: (2021)

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
por: Xuan Zhou, et al.
Publicado: (2021)

Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis‐related genes
por: Xiayao Diao, et al.
Publicado: (2021)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
por: Sergey V. Goryaynov
Publicado: (2021)

Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury
por: Vanessa Zambelli, et al.
Publicado: (2021)

Clopidogrel-Induced Interstitial Lung Disease: A Case Report
por: An J, et al.
Publicado: (2021)

Diallyl Sulfide-Mediated Modulation of the Fatty Acid Synthase (FASN) Leads to Cancer Cell Death in BaP-Induced Lung Carcinogenesis in Swiss Mice
por: Khan A, et al.
Publicado: (2020)

Development and Validation of a Novel Nomogram for Predicting Tumor-Distant-Metastasis in Patients with Early T1-2 Stage Lung Adenocarcinoma
por: Gu W, et al.
Publicado: (2020)

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
por: Oh F, et al.
Publicado: (2018)

Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapy
por: North WG, et al.
Publicado: (2019)

Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer
por: Ying Liu, et al.
Publicado: (2022)

Identification of an Innate Immune-Related Prognostic Signature in Early-Stage Lung Squamous Cell Carcinoma
por: Li L, et al.
Publicado: (2021)

Advances and challenges in the treatment of esophageal cancer
por: Shiming He, et al.
Publicado: (2021)

Acantholytic Squamous Cell Carcinoma
por: Sandy Maganito, et al.
Publicado: (2021)

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
por: Huanhuan Xu, et al.
Publicado: (2021)

Survival-associated N6-adenosine methyltransferase signatures in lung squamous cell carcinoma and clinical verification
por: Jialin Qu, et al.
Publicado: (2021)

Roles of mesenchymal stromal cells in the head and neck cancer microenvironment
por: Marcelo Coutinho de Miranda, et al.
Publicado: (2021)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang SS, et al.
Publicado: (2021)

Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
por: Thakur MK, et al.
Publicado: (2017)

Construction of a prognostic model for lung squamous cell carcinoma based on seven N6-methylandenosine-related autophagy genes
por: Xin Yu, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
por: Maja Šutić, et al.
Publicado: (2021)